Edesa Biotech (EDSA) EBITDA (2013 - 2026)

Edesa Biotech has disclosed EBITDA across 14 years of filings, most recently posting -$5.5 million for Q2 2026.

• In Q2 2026, EBITDA fell 189.93% year-over-year to -$5.5 million; the TTM figure through Jun 2026 stood at -$12.2 million (down 89.81% YoY), while the FY2025 annual figure was -$7.9 million, down 12.78% from the prior year.
• EBITDA came in at -$5.5 million for Q2 2026 at Edesa Biotech, down from -$2.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.0 million in Q3 2024 to a low of -$5.8 million in Q2 2022.
• Average EBITDA over 5 years is -$2.7 million, with a median of -$2.3 million recorded in 2025.
• Year-over-year, EBITDA surged 64.39% in 2023 and plunged 189.93% in 2026.
• Over 5 years, EBITDA stood at -$2.4 million in 2022, then rose by 21.9% to -$1.9 million in 2023, then dropped by 2.22% to -$1.9 million in 2024, then dropped by 23.32% to -$2.3 million in 2025, then slumped by 135.74% to -$5.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.5 million in Q2 2026, -$2.3 million in Q4 2025, and -$2.5 million in Q3 2025.